Title: Small Interfering RNA Libraries and Methods of Synthesis and Use
Filed: May 10, 2004
Lead Inventor: Mark Nichols, University of Pittsburgh
According to the patent's abstract, "the invention provides a random or semi-random siRNA-encoding library." Other aspects of the invention pertain to "methods for construction of random or semi-random siRNA-encoding libraries … vector systems for use in constructing siRNA libraries … that can express single siRNAs and siRNA libraries both constitutively and in an inducible fashion … [and] a method of using an siRNA library.
A method of the invention includes introducing an siRNA library into a population of cells, which is then is subjected to a selection process to select a subpopulation of cells exhibiting a different behavioral, biochemical, chemical, functional, molecular, morphological, phenotypic, or physical property from the remainder of population, the abstract notes. "Following the selection process, the subpopulation of cells can be isolated, analyzed, and/or cloned as desired. Such analysis of the subpopulation can be identification and sequencing of the siRNA species responsible for the different properties of the subpopulation relative to the remainder of the population. Alternatively, the subpopulation can be further analyzed by genomic, proteomic, and/or cellomic assays."
Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
Filed: Dec. 4, 2008
Lead Inventor: Michael Tolentino, University of Pennsylvania (Opko Health)
The patent application, its abstract states, claims "RNA interference using small interfering RNAs … specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR [to] inhibit expression of these genes. Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs."
Title: Compositions and Methods for siRNA Inhibition of ICAM-1
Filed: Dec. 5, 2008
Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)
According to the patent application's abstract, the invention comprises "RNA interference using small interfering RNAs … specific for the ICAM-1 gene [to inhibit] expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs."
[ pagebreak ]
Title: Nucleic Acids Hybridizable to microRNA and Precursors Thereof
Filed: April 18, 2008
Inventor: Sumedha Jayasena, Amgen
The patent application, its abstract states, claims "methods and compositions relating to nucleic acids targeting certain miRNA molecules. …The nucleic acids are useful in methods of increasing nuclear concentration of FKHR protein, decreasing cell viability, and treating cancer."
Titles: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure
Numbers: 20090105175, 20090105176
Filed: July 9, 2008
Lead Inventor: Ana Jimenez, Sylentis
The inventions, the patent applications' abstracts state, relate to "methods and compositions that decrease intraocular pressure of the eye. The compositions of the invention comprise short interfering nucleic acid molecules including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP, such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention."
Title: RNA Interference-Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor Gene Expression Using Short Interfering Nucleic Acid
Filed: Sept. 4, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of ECGF1 and/or ECGF1r genes."
Title: RNAi-Mediated Inhibition of Stromal Cell-Derived Factor 1-Related Targets for Treatment of Neovascularization-Related Conditions
Filed: June 1, 2007
Lead Inventor: Jon Chatterton, Alcon
The patent application, the abstract states, claims "RNA interference … for inhibition of stromal cell-derived factor 1-related targets in pathologic neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the SDF1 targets that lead directly or indirectly to ocular neovascularization, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy, particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization, for example."
[ pagebreak ]
Title: Influenza Therapeutic
Filed: Dec. 6, 2007
Lead Inventor: Jianzhu Chen, Massachusetts Institute of Technology
The invention, the patent application's abstract states, claims "methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference, [as] well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity, and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells," it adds. "In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza."